Rick L. work email
- Valid
- Valid
- Valid
- Valid
Rick L. personal email
Rick L. phone numbers
Results-focused biopharma entrepreneur with 30+ years of early-stage company-building experience and a successful track record developing strategic business plans, raising capital, and creating value through team building, operational excellence and strategic partnerships and M&A. Navitor Pharma founding team member with overall responsibility for strategy, corporate and business development, finance, operations and legal/administration. Raised over $100M in equity capital and closed partnering transactions with total potential value of nearly $1B.Prior to joining Navitor, founded 7S BioVentures, providing strategy, deal-making and executional leadership to established and emerging Life Sciences companies and investors. From 2006 to 2009, responsible for ex-U.S. commercial strategy and business development at Targanta Therapeutics (acquired by The Medicines Company). Previously, led therapeutics business development initiatives and managed the genomics services business at Celera Genomics. Before that, nearly a decade at Biogen in a broad range of business roles, including business development, program management, investor relations, sales and marketing.BA in Biochemical Sciences from Harvard University.
-
President And CeoEikonizo TherapeuticsLexington, Ma, Us
-
President & CeoEikonizo Therapeutics Aug 2022 - PresentCambridge, Ma, UsEikonizo is developing highly selective, brain-penetrant small molecule histone deacetylase 6 (HDAC6) inhibitors as disease-modifying therapeutics for neurodegenerative disease, including amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy (CIPN) and Alzheimer’s disease as well as peripherally-restricted HDAC6 inhibitors for ADPKD, cardiac and other indications.
-
President7S Bioventures 2005 - PresentProviding strategy, deal-making and executional leadership to established and emerging Life Sciences companies and investors. Projects have included:• Closed seed financing for Polaris-incubated NewCo (now Navitor); led creation of initial business plan and joined company full-time after closing Series A.• Start-Up CEO role for seed-stage venture developing novel protein therapeutics for the treatment and repair of ischemic injury.• Led BD efforts for venture-backed company developing an unique infusion system for SC delivery of high volume/viscosity drugs based on MIT scientific founder's IP.• Led creation and execution of strategy to partner company’s lead antibiotic compounds and other compounds derived from technology platform.• Led creation of initial business plan for a venture-incubated NewCo based on Harvard scientific founder's IP.• Developed strategic plan for a novel clinical-stage neurotherapeutic.• Key strategic and operational role incubating a seed-stage company developing an all-digital surgical microscope for ophthalmic and other surgeries.
-
Svp, Corporate Development; Secretary And TreasurerNavitor Pharmaceuticals Sep 2013 - Mar 2022Cambridge, Ma, UsFounding team member with overall responsibility for strategy, corporate and business development, finance, operations and legal/administration. Raised over $100M in equity capital and closed partnering transactions with total potential payments of nearly $1B including: Development and Option Agreement with Supernus Pharma (NV-5138 for TRD), and; spin-off and sale of Anakuria Tx (NV-20494 for ADPKD) to Janssen Pharma. -
Director, Business DevelopmentTarganta Therapeutics Nov 2006 - Feb 2009Cambridge, Ma, UsReporting to CEO, led strategy development and execution, including primary negotiating responsibility, for ex-US partnerships for oritavancin, Targanta’s antibiotic for serious gram positive infections including MRSA.Targanta was acquired by The Medicines Company in Feb '09 and ORBACTIV®(oritavancin) was approved in the US in Aug'14 and EU in Mar'15. -
Various PositionsCelera Genomics 2000 - 2004Led creation and implementation of Celera’s initial biopharma collaborative partnering strategy to leverage Celera's knowledge of the human genome in drug development. Provided business development and strategy support for Celera’s proteomics target discovery, oncology and virology programs. P&L responsibility for Celera’s contract services business including sequencing & genotyping; grew revenues by 50% and brought business to profitability before divesting business. -
Various PositionsBiogen 1990 - 2000Cambridge, Ma, UsBroad range of business roles including business development, program management, investor relations, sales and marketing. -
Research TechnicianHarvard Medical School 1987 - 1989Boston, Ma, UsRemold-O'Donnell Lab, Center for Blood Research. Characterized novel serine protease inhibitors.
Rick L. Skills
Rick L. Education Details
-
Harvard UniversityBiochemical Sciences
Frequently Asked Questions about Rick L.
What company does Rick L. work for?
Rick L. works for Eikonizo Therapeutics
What is Rick L.'s role at the current company?
Rick L.'s current role is President and CEO.
What is Rick L.'s email address?
Rick L.'s email address is rl****@****rma.com
What is Rick L.'s direct phone number?
Rick L.'s direct phone number is +161786*****
What schools did Rick L. attend?
Rick L. attended Harvard University.
What skills is Rick L. known for?
Rick L. has skills like Lifesciences, Drug Development, Pharmaceutical Industry, Biopharmaceuticals, Life Sciences, Biotechnology, Business Development, Strategic Alliances, Strategy, Biochemistry, Entrepreneurship, Product Management.
Who are Rick L.'s colleagues?
Rick L.'s colleagues are Lauren Evans, Rebecca James (She/her), Ph.d..
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial